Botanix Pharmaceuticals (BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US Food and Drug Administration (FDA).
Source: https://themarketherald.com.au/botanix-pharmaceuticals-asxbot-suffers-setback-in-fda-approval-for-sofpironium-bromide-gel-to-treat-hyperhidrosis-2023-09-26/
Bot Chart, page-10609
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $592.7M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $1.139M | 3.471M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 881006 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 416820 | 13 |
View Market Depth
| Last trade - 15.38pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |